Literature DB >> 1298217

Prevention of Lyme disease after tick bites. A cost-effectiveness analysis.

D Magid1, B Schwartz, J Craft, J S Schwartz.   

Abstract

BACKGROUND: In areas of endemic disease, the probability of Lyme disease after a tick bite ranges from about 0.012 to 0.05. Early treatment with oral antibiotics prevents most complications of Lyme disease, but antibiotics are generally not prescribed until rash or other symptoms develop.
METHODS: We used decision analysis to evaluate the outcomes, costs, and cost effectiveness of three alternative strategies to treat patients bitten by ixodes ticks in areas of endemic Lyme disease: empirically treat all patients with two weeks of doxycycline, treat only patients in whom erythema migrans develops, and treat only patients with erythema migrans or a positive serologic test for Lyme disease one month after exposure.
RESULTS: Empirical treatment is the least expensive strategy and results in the fewest cases of Lyme disease and the fewest complications when the probability of Borrelia burgdorferi infection after a tick bite is 0.036 or higher. For probabilities of infection below 0.036, empirical therapy prevents most major complications, sequelae, and adverse events, but it incurs additional minor complications, especially as the probability of infection falls below 0.01.
CONCLUSIONS: Empirical treatment of patients with tick bites is indicated when the probability of B. burgdorferi infection after a bite is 0.036 or higher, and this treatment may be preferred when the probability of infection ranges from 0.01 to 0.035. When the probability of infection after a tick bite is less than 0.01, empirical therapy is not warranted.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1298217     DOI: 10.1056/NEJM199208203270806

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  27 in total

Review 1.  Bacteria-Triggered reactive arthritis: implications for antibacterial treatment.

Authors:  A Toivanen
Journal:  Drugs       Date:  2001       Impact factor: 9.546

2.  [Multiple erythema].

Authors:  B Brunner; U Neubert; M J Flaig; C A Sander
Journal:  Hautarzt       Date:  2003-03-25       Impact factor: 0.751

Review 3.  Treatment of Lyme arthritis.

Authors:  M A Cimmino; G L Moggiana; M Parisi; S Accardo
Journal:  Infection       Date:  1996 Jan-Feb       Impact factor: 3.553

Review 4.  Management of childhood arthritis. Part 1: Acute arthritis.

Authors:  P N Malleson
Journal:  Arch Dis Child       Date:  1997-05       Impact factor: 3.791

5.  Adjuvanted Lyme disease vaccine: a review of its use in the management of Lyme disease.

Authors:  S V Onrust; K L Goa
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

6.  Fetal outcome in murine Lyme disease.

Authors:  R M Silver; L Yang; R A Daynes; D W Branch; C M Salafia; J J Weis
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441

7.  Unusual features in the epidemiology of Lyme borreliosis.

Authors:  L Angelov
Journal:  Eur J Epidemiol       Date:  1996-02       Impact factor: 8.082

8.  Medical decision analysis in infectious diseases.

Authors:  U D Allen
Journal:  Can J Infect Dis       Date:  2000-11

9.  Risk of Borrelia burgdorferi infection in western Switzerland following a tick bite.

Authors:  I Nahimana; L Gern; D S Blanc; G Praz; P Francioli; O Péter
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-07-24       Impact factor: 3.267

10.  Applying decision analysis to management of adolescent idiopathic nephrotic syndrome.

Authors:  M M Moxey-Mims; F B Stapleton; L G Feld
Journal:  Pediatr Nephrol       Date:  1994-12       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.